Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 578

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 578
---
 ​ | 18%      | ​ | ​ | ​    | $ | 91,879 | ​ | ​ | ​ | 11%      | ​ |

(1) Includes milestone payments of $5.0 million and $15.0 million to Enteris for the year ended December 31, 2022.

332

TABLE OF CONTENTS

General and Administrative Expense

| ​                                               
 ​                                               | ​ 
 ​ | ​ 
 ​ | Year Ended December 31,     
 2023                        |   |        |   |   |   |          |   |       |   | ​ | ​ | 2022 |   |        |   |   |   |          |   |       |   | ​ 
 ​ |
|:------------------------------------------------|:--|:--|:----------------------------|:--|-------:|:--|:--|:--|:---------|:--|:------|:--|:--|:--|:-----|:--|-------:|:--|:--|:--|:---------|:--|:------|:--|:--|
| ​                                               | ​ | ​ | Dollar amounts in thousands |   |        |   |   |   |          |   |       |   |   |   |      |   |        |   |   |   |          |   |       |   | ​ |
| ​                                               | ​ | ​ | ​                           | ​ |      ​ | ​ | ​ | ​ | % change |   |       |   | ​ | ​ | ​    | ​ |      ​ | ​ | ​ | ​ | % change |   |       |   | ​ |
| Professional fees and public/investor relations | ​ | ​ | ​                           | $ |  6,228 | ​ | ​ | ​ | ​        | ​ | (1)%  | ​ | ​ | ​ | ​    | $ |  6,322 | ​ | ​ | ​ | ​        | ​ | 36%   | ​ | ​ |
| Stock-based compensation                        | ​ | ​ | ​                           | ​ |  7,281 | ​ | ​ | ​ | ​        | ​ | (25)% | ​ | ​ | ​ | ​    | ​ |  9,747 | ​ | ​ | ​ | ​        | ​ | (22)% | ​ | ​ |
| Depreciation and amortization                   | ​ | ​